Anti-vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market By Drug Type (Monoclonal Antibodies, Recombinant Fusion Proteins, Small Molecule Inhibitors, Biosimilars); By Route of Administration (Intravitreal Injection, Intravenous Infusion, Oral); By Application (Ophthalmology [AMD, DME, RVO], Oncology [Colorectal Cancer, NSCLC, RCC, Others]); By End User (Hospitals, Specialty Clinics, ASCs, Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Anti-Vascular Endothelial Growth Factor (Anti - VEGF) Therapeutics Market will witness a robust CAGR of 7.8%, valued at $13.2 billion in 2024 , and is expected to appreciate and reach $20.7 billion by 2030 , confirms Strategic Market Research.

 

Anti-VEGF therapeutics are a class of biologics that inhibit the activity of VEGF — a signaling protein that promotes the growth of new blood vessels. Originally designed to combat tumor angiogenesis in cancer, Anti-VEGF drugs have become cornerstone treatments in ophthalmology, particularly for age-related macular degeneration (AMD) , diabetic macular edema (DME) , and retinal vein occlusion (RVO) . Their use in oncology, notably in colorectal, renal, and non-small cell lung cancers, also drives market relevance.

 

Strategic Relevance

In 2024, this market's importance stems from the intersection of multiple macro forces:

• Aging demographics : The prevalence of retinal vascular disorders is increasing rapidly due to the global aging population.

• Oncology burden : Rising cancer incidence has underscored the need for effective angiogenesis inhibitors in chemotherapy regimens.

• Technological advancement : Biosimilar developments, sustained-release formulations, and targeted delivery systems are reshaping therapeutic profiles.

• Healthcare policy evolution : Governments and health systems worldwide are integrating Anti-VEGF drugs into public coverage models, improving access and adoption.

Key stakeholders include:

• Pharmaceutical and biotech manufacturers (both originators and biosimilar developers)

• Healthcare providers (ophthalmologists, oncologists, general hospitals, clinics)

• Regulatory agencies (e.g., FDA, EMA, PMDA)

• Payers and insurance providers

• Private investors and research consortia

The market's dual utility across chronic ophthalmic disorders and life-threatening cancers makes it strategically resilient and primed for clinical and commercial innovation. With maturing biologic pipelines, global healthcare infrastructure scaling, and biosimilar acceptance growing, Anti-VEGF therapeutics are positioned as essential in next-gen treatment protocols.

 

Market Segmentation And Forecast Scope

The anti-vascular endothelial growth factor (Anti-VEGF) therapeutics market is defined by a multidimensional segmentation structure that reflects the drug class's therapeutic diversity, delivery complexity, and end-user patterns. To enable an accurate market forecast and strategic assessment, the market is segmented as follows:

By Drug Type

• Monoclonal Antibodies

• Recombinant Fusion Proteins

• Small Molecule Inhibitors

• Biosimilars

Monoclonal antibodies (e.g., bevacizumab) account for the largest revenue share of over 46% in 2024 , owing to their established use in oncology and ophthalmology. However, the biosimilars segment is projected to be the fastest-growing over the forecast period, driven by patent expiries of blockbuster biologics and cost-containment efforts by health authorities globally.

 

By Route of Administration

• Intravitreal Injections

• Intravenous Infusion

• Oral

Intravitreal injection remains the dominant route, especially in ophthalmology, due to its localized delivery advantage and improved drug retention in ocular tissues. Although intravenous delivery dominates in oncology, there's growing R&D in oral VEGF inhibitors aiming to enhance patient compliance.

 

By Therapeutic Application

• Ophthalmology

• Age-Related Macular Degeneration (AMD)

• Diabetic Macular Edema (DME)

• Retinal Vein Occlusion (RVO)

• Oncology

• Colorectal Cancer

• Non-Small Cell Lung Cancer (NSCLC)

• Renal Cell Carcinoma (RCC)

• Others

The ophthalmology segment dominates in volume terms, while oncology leads in revenue due to higher treatment costs per cycle. Among ophthalmic disorders, AMD represents the single largest sub-application by value and volume. Emerging research in combining anti-VEGF with checkpoint inhibitors in oncology offers future synergistic potential.

 

By End User

• Hospitals

• Specialty Clinics

• Ambulatory Surgical Centers (ASCs)

• Research Institutes

Hospitals remain the core adoption centers , especially for cancer therapies requiring infusion support. However, specialty eye clinics are growing rapidly due to their concentration of retinal specialists and outpatient-friendly administration setups.

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

North America is projected to account for the highest market share in 2024 , supported by early biologic adoption, high awareness, and payer reimbursement frameworks. Meanwhile, Asia-Pacific is forecast to be the fastest-growing region due to expanding aging demographics, increasing diabetic populations, and improving diagnostic access.

This segmentation framework enables stakeholders to pinpoint strategic opportunities—whether it be innovating with next-gen biologics, localizing biosimilar production, or capturing unmet ophthalmologic needs in emerging markets.

 

Market Trends And Innovation Landscape

The anti-vascular endothelial growth factor (Anti-VEGF) therapeutics market is undergoing a pivotal transformation driven by molecular innovation, biosimilar disruption, and expanding clinical indications. Across both ophthalmology and oncology, the next wave of growth is being shaped by scientific advances and ecosystem-level shifts that favor accessibility, durability, and personalized targeting.

1. Rise of Biosimilars and Cost Efficiency

One of the most profound developments in this market is the commercialization of biosimilars for leading anti-VEGF agents such as bevacizumab and ranibizumab. These biosimilars offer similar efficacy at lower cost, accelerating uptake in price-sensitive markets and encouraging payer-driven switching in developed economies.

“Biosimilars are not just disrupting cost models—they are expanding the addressable base of patients previously excluded due to affordability barriers,” notes a senior pharmacoeconomics analyst from Europe.

 

2. Innovations in Sustained-Release Delivery

A major limitation of current Anti-VEGF therapies, particularly in ophthalmology, is the frequent need for intravitreal injections , often monthly. In response, R&D efforts are focusing on:

• Implantable slow-release devices (e.g., refillable ocular ports)

• Biodegradable microspheres

• Longer-acting fusion proteins with extended intraocular half-life

These platforms reduce treatment burden, enhance patient compliance, and improve clinic efficiency.

 

3. Dual-Target and Combination Therapies

Researchers are increasingly exploring dual-target biologics that inhibit VEGF alongside other angiogenic or inflammatory pathways (e.g., Ang-2, PDGF). Additionally, Anti-VEGF agents are being evaluated in combination with checkpoint inhibitors and tyrosine kinase inhibitors in oncology to overcome drug resistance and improve survival outcomes.

“Combination therapy will redefine the clinical ceiling of Anti-VEGF efficacy, especially in tumors that exhibit angiogenic plasticity,” suggests an oncology investigator from a global cancer center .

 

4. Digital Health and AI-Powered Monitoring

In ophthalmology, the integration of AI-based retinal imaging platforms is transforming diagnostics and disease progression monitoring. These systems can identify microvascular changes and recommend Anti-VEGF therapy timing, enhancing precision and outcomes.

In parallel, electronic health records (EHRs) and e-prescribing platforms are being aligned to support biosimilar tracking, patient adherence analytics, and treatment pathway optimization.

 

5. Strategic Partnerships and Pipeline Acceleration

Recent years have witnessed intensified collaborations among pharma giants, biotech startups, and academic institutes to co-develop novel VEGF inhibitors or expand into new indications (e.g., rare vascular tumors , inflammatory disorders). Noteworthy innovation partnerships have focused on gene therapy approaches aiming to induce endogenous anti-VEGF effects with a single administration.

 

Summary Innovation Snapshot:

Innovation Vector	Key Development
Biosimilars	Affordable access, high uptake post-patent
Drug Delivery	Implants, hydrogels, biodegradable carriers
Dual-Pathway Targeting	VEGF + Ang-2/PDGF inhibition
Digital Integration	AI-assisted diagnostics, EHR mapping
Partnerships & Licensing	Oncology-ophthalmology crossover initiatives

Collectively, these trends indicate a market shifting from monotherapy saturation to a dynamic ecosystem characterized by affordability, durability, and precision medicine. Innovation is no longer centered on VEGF inhibition alone—it now encompasses the how, when, and where of therapeutic administration.

 

Competitive Intelligence And Benchmarking

The anti-vascular endothelial growth factor (Anti-VEGF) therapeutics market is characterized by an evolving competitive landscape dominated by a mix of multinational pharmaceutical leaders, specialized biotech firms, and emerging biosimilar developers. The key strategic battlegrounds include innovation in drug design, differentiation in delivery platforms, and regional biosimilar penetration.

Roche (Genentech)

Roche remains a dominant force through its Genentech subsidiary, which developed bevacizumab (Avastin) and ranibizumab (Lucentis) —two cornerstone Anti-VEGF agents. The company maintains a robust global footprint with innovation hubs across the U.S. and Europe. While Lucentis retains strong ophthalmic market share, Roche is pivoting towards extended-delivery platforms and next-gen dual-inhibition therapies. It also introduced faricimab , a bispecific antibody targeting both VEGF-A and Ang-2.

 

Regeneron Pharmaceuticals

Regeneron leads in ophthalmology with aflibercept , marketed as Eylea, a recombinant fusion protein with high binding affinity. The firm’s success stems from deep specialization, strategic marketing partnerships (notably with Bayer outside the U.S.), and consistent clinical trial innovation. Its recent development of Eylea HD (a high-dose formulation) reinforces its positioning in the durability race.

 

Pfizer

Through early licensing deals and oncology-focused development, Pfizer has been a key player in the Anti-VEGF space, particularly in renal and lung cancer treatment . The company strategically leverages its global distribution network and oncology alliance portfolio to drive label expansions and combination studies.

 

Samsung Bioepis

A pivotal player in the biosimilars domain , Samsung Bioepis has gained regulatory traction for bevacizumab biosimilars in multiple geographies. Its partnerships with firms like Biogen enable rapid commercialization and competitive pricing strategies in Europe and Asia.

 

Amgen

Amgen focuses on both innovator molecules and biosimilars. It has actively developed biosimilar versions of bevacizumab, positioning itself as a value player in both oncology and ophthalmology segments. The firm invests heavily in manufacturing scalability and market access programs.

 

Novartis

While Novartis initially co-marketed Lucentis outside the U.S., it has now expanded its ophthalmology pipeline with sustained-release innovations and global trials. It also engages in digital health integration to improve retinal disease management.

 

Biocon Biologics

An emerging force from Asia, Biocon Biologics has made strategic moves into bevacizumab biosimilars, targeting affordability-driven regions like India, Southeast Asia, and parts of Africa. Its value chain control—from R&D to distribution—offers significant cost leverage.

 

Strategic Benchmarks

Company	Innovation Focus	Regional Focus	Unique Strategy
Roche	Dual-target biologics, depot systems	U.S., EU	Brand legacy + pipeline integration
Regeneron	Long-acting formats	North America, Europe	Clinical data strength + strategic partnerships
Pfizer	Oncology expansion	Global	Combo therapy studies
Samsung Bioepis	Biosimilars	Asia, Europe	Low-cost access + rapid approval path
Amgen	Biosimilar volume scale	U.S., LATAM, APAC	Tech-agnostic production capabilities
Novartis	Ocular tech integration	Global	Digital diagnostics synergy
Biocon Biologics	Emerging market leadership	India, Africa, SEA	Affordable oncology care models

What distinguishes this market is the fusion of biologics innovation and biosimilar agility. Companies that balance scientific leadership with scalable pricing models are best positioned for long-term competitiveness.

 

Regional Landscape And Adoption Outlook

The adoption and growth of anti-vascular endothelial growth factor (Anti-VEGF) therapeutics vary significantly across global regions due to differences in disease prevalence, healthcare infrastructure, regulatory maturity, and reimbursement mechanisms. While high-income regions dominate early innovation and market penetration, emerging economies are rapidly increasing access through biosimilars and public health integration.

North America

North America leads the global Anti-VEGF therapeutics market, accounting for over 40% of total revenue share in 2024 . The U.S., in particular, benefits from:

• High incidence of AMD , diabetic retinopathy , and solid tumors

• Advanced diagnostic imaging infrastructure for early detection

• FDA-approved portfolio of innovator and biosimilar Anti-VEGF agents

• Strong commercial insurance coverage and Medicare support

The region is also a nucleus for clinical trials, hosting major oncology and ophthalmology research centers . Canada follows similar trends, albeit with more centralized price regulation via the Patented Medicine Prices Review Board (PMPRB) .

 

Europe

Europe holds the second-largest market share , with widespread adoption in Germany , France , UK , and the Nordics . Key regional drivers include:

• Universal healthcare systems with reimbursement for Anti-VEGF agents

• Accelerated biosimilar approvals through the European Medicines Agency (EMA)

• High aging population leading to a rise in age-related vision loss

• Cross-border collaborations for oncological trials

The European market is also highly price-sensitive, creating fertile ground for biosimilar competition. Countries like the UK and Sweden are actively promoting biosimilar uptake to reduce the overall biologics burden on public systems.

 

Asia-Pacific

Asia-Pacific (APAC) is the fastest-growing region , projected to expand at a CAGR exceeding 10% through 2030 . This surge is driven by:

• Rising prevalence of diabetes-induced eye diseases

• Large aging populations in Japan , China , and South Korea

• Expanding oncology burden and urban cancer centers

• Improved access to biosimilars through local manufacturing incentives

Japan leads the region in terms of innovation and adoption, while China’s government push for low-cost biosimilars is reshaping pricing models. India is emerging as both a manufacturing hub and a high-growth end-user market due to government-subsidized cancer and vision care programs.

 

Latin America

Growth in Latin America remains moderate, with countries like Brazil , Mexico , and Argentina investing in improving access to Anti-VEGF therapies via public-private partnerships. However, challenges persist:

• High out-of-pocket expenditure

• Uneven distribution of retinal specialists

• Delays in biosimilar approval timelines

Despite this, Brazil is expected to lead regional expansion through regulatory reforms and expanded coverage in its Sistema Único de Saúde (SUS) public health program.

 

Middle East & Africa (MEA)

The MEA region represents a small yet rising market opportunity. Key developments include:

• Gulf countries (UAE, Saudi Arabia) investing in specialty ophthalmic centers

• South Africa expanding its oncology formulary to include more biologics

• Regional biosimilar programs aiming to overcome cost and access barriers

That said, healthcare disparities and infrastructure deficits across Sub-Saharan Africa still limit Anti-VEGF therapeutic access, especially outside urban hubs.

 

Regional Summary Snapshot

Region	2024 Market Share	Growth Drivers	Key Challenge
North America	High	Innovation, reimbursement, clinical infrastructure	Rising biologics cost burden
Europe	Moderate–High	EMA biosimilar policies, public healthcare systems	Price pressures and formulary delays
Asia-Pacific	Fastest Growing	Aging, diabetes, biosimilar localization	Limited rural access and diagnosis gaps
Latin America	Moderate	Government partnerships, expanding vision care	Infrastructure disparity, access costs
MEA	Low but Rising	Specialty centers in GCC, oncology expansion	Funding gaps, workforce shortage

The regional outlook reveals a dichotomy: mature markets are focusing on cost control and advanced delivery, while emerging regions emphasize accessibility and biosimilar adoption. Market players must tailor strategies to each geography’s unique regulatory and clinical landscape.

 

End-User Dynamics And Use Case

The anti-vascular endothelial growth factor (Anti-VEGF) therapeutics market is strongly shaped by end-user behavior , influenced by treatment type, disease burden, infrastructure availability, and clinical specialization. From high-volume hospitals to specialized retinal clinics, understanding how each stakeholder engages with Anti-VEGF therapy is critical for optimizing distribution, education, and therapeutic outcomes.

1. Hospitals

Hospitals—especially tertiary and quaternary care centers —are the largest consumers of Anti-VEGF agents, particularly in oncology applications . These institutions administer VEGF inhibitors via intravenous infusions as part of cancer chemotherapy regimens. They are also the primary sites for clinical trials and early access programs. Hospitals tend to favor branded drugs due to institutional procurement protocols, although budget-constrained systems are now piloting biosimilar integration to manage biologics expenditure.

 

2. Specialty Clinics

Retinal and ophthalmology clinics are crucial in the ophthalmic segment. They often deliver intravitreal injections for chronic conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME) . These clinics value long-acting formulations that reduce injection frequency and patient burden. The clinical workflow is streamlined, allowing for rapid turnover, making them attractive points for commercial outreach and patient education programs.

 

3. Ambulatory Surgical Centers (ASCs)

ASCs provide outpatient therapeutic administration, often specializing in ophthalmic procedures. These centers benefit from low operating costs, shorter patient stays, and increasing access to Anti-VEGF biologics. ASCs are well-positioned to serve growing elderly populations that prefer outpatient care for vision preservation therapies.

 

4. Research Institutes

Academic and translational research centers play a strategic role by conducting pivotal Phase II/III trials. These institutions shape treatment guidelines, explore VEGF inhibition in novel indications , and support companion diagnostics. Their adoption patterns influence regulatory policies and payer reimbursements globally.

 

Real-World Use Case

A tertiary hospital in South Korea launched a national screening program for early detection of diabetic retinopathy in adults over 50. Utilizing AI-assisted fundus cameras, patients diagnosed with diabetic macular edema (DME) were promptly scheduled for Anti-VEGF intravitreal injection therapy using biosimilar ranibizumab. Over a 12-month period, the program led to:

• 35% improvement in early-stage DME detection

• 30% reduction in hospital revisit rates due to optimized treatment intervals

• Significant patient satisfaction gains , with over 70% preferring continued biosimilar therapy due to reduced cost and visual function stabilization

This case highlights how technology-aided diagnostics and biosimilar availability are transforming end-user dynamics and healthcare equity in Asia.

 

End-User Summary

End User Type	Primary Role	Strategic Advantage
Hospitals	Oncology infusions, trial sites	Volume capacity, payer alignment
Specialty Clinics	Ophthalmology-focused administration	Speed, specialization, compliance optimization
ASCs	Outpatient anti-VEGF procedures	Cost-efficiency, aging patient population
Research Institutes	Clinical research and validation	Innovation hub, guideline influence

Understanding these adoption dynamics enables manufacturers to customize access models—from bulk hospital supply agreements to clinic-specific patient adherence solutions.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

The anti-vascular endothelial growth factor (Anti-VEGF) therapeutics market has witnessed notable advancements in clinical approvals, biosimilar introductions, and delivery innovations. Below are five key developments shaping the landscape between 2023 and 2025:

• FDA Approval of Aflibercept 8 mg (Eylea HD) Regeneron received FDA approval for a high-dose aflibercept formulation, offering extended dosing intervals of up to 16 weeks for patients with wet AMD and DME—improving compliance and reducing clinic visits.

• EMA Authorization of Bevacizumab Biosimilar from Samsung Bioepis The European Medicines Agency approved SB8 , a bevacizumab biosimilar developed by Samsung Bioepis , broadening access across oncology indications in Europe.

• Launch of Faricimab in Multiple Regions by Roche Faricimab , a first-in-class bispecific antibody targeting both VEGF-A and Ang-2, has launched in key markets such as the U.S., UK, and Japan for wet AMD and DME, offering durability and dual-pathway inhibition.

• India Approves Bevacizumab Biosimilar by Biocon Biologics Biocon’s bevacizumab biosimilar received regulatory approval in India, supporting oncology affordability initiatives and expanding biosimilar market share in South Asia.

• Ongoing Trials of Gene Therapy-Based VEGF Suppression (RGX-314) Regenxbio’s experimental gene therapy for wet AMD (RGX-314), which induces long-term anti-VEGF protein expression in retinal cells, entered late-stage trials in 2024.

 

Opportunities

• Expansion into Emerging Markets via Biosimilars As intellectual property protections expire, biosimilar Anti-VEGF therapies are enabling price-sensitive markets—particularly in Latin America, Southeast Asia, and Africa—to offer advanced biologic care at sustainable costs.

• Growth of Long-Acting and Dual-Inhibition Platforms Sustained-release Anti-VEGF delivery systems and bispecific molecules offer extended dosing schedules, which significantly reduce treatment fatigue and healthcare system burden.

• AI-Driven Patient Monitoring and Personalized Dosing Integration of imaging AI and real-world analytics is transforming treatment regimens from fixed to personalized dosing strategies , optimizing both outcomes and costs.

 

Restraints

• Regulatory Delays for Biosimilar Approvals in Some Regions Stringent biologics review timelines and inconsistent pharmacovigilance infrastructure in parts of Latin America and Africa hinder biosimilar rollout and scale-up.

• High Cost of Innovator Therapies in Uninsured Populations Despite biosimilar advances, out-of-pocket costs for branded Anti-VEGF agents remain prohibitive in countries with limited insurance coverage, restricting access to cutting-edge care.

These recent events and structural dynamics underline a market in flux—where access, innovation, and policy reform converge to shape the next phase of therapeutic expansion.
 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 13.2 Billion
Revenue Forecast in 2030	USD 20.7 Billion
Overall Growth Rate	CAGR of 7.8% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Drug Type, By Route of Administration, By Application, By End User, By Geography
By Drug Type	Monoclonal Antibodies, Recombinant Fusion Proteins, Small Molecule Inhibitors, Biosimilars
By Route of Administration	Intravitreal Injection, Intravenous Infusion, Oral
By Application	Ophthalmology (AMD, DME, RVO), Oncology (Colorectal Cancer, NSCLC, RCC, Others)
By End User	Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, South Korea, GCC, South Africa
Market Drivers	- Rise in aging population and vision disorders - Expanding oncology burden - Increasing biosimilar adoption
Customization Option	Available upon request